ScreenerHero

MGTX MeiraGTx Holdings plc

NAS · US · Healthcare · Biotechnology · meiragtx.com
10.82USD+2.08%Mkt Cap: 1.04B $P/E: 12.44

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited ret…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.04B USD
Enterprise Value987.42M USD
Revenue (TTM)397.50M USD
Gross Profit76.55M USD
Net Income (TTM)-114.20M USD
Revenue/Share4.75 USD
Last Price10.82 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees393
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)12.44
P/E (Forward)-6.95
PEG—
EV/EBITDA5.03
EV/Revenue2.48
P/S2.56
P/B4.63
EPS (TTM)0.87
EPS (Forward)-1.52
52W Range
6.62048% of range15.35
52W High15.35 USD
52W Low6.620 USD
Profitability
Gross Margin94.05%
Oper. Margin76.04%
EBITDA Margin49.34%
Profit Margin-140.31%
ROE1971.36%
ROA-46.72%
Growth
Revenue Growth8608.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-46.36M USD
CapEx (TTM)4.24M USD
FCF Margin14.19%
FCF Yield5.43%
Net Debt-30.84M USD
Net Debt/EBITDA-0.16
Balance Sheet
Debt/Equity-15.31
Current Ratio3.76
Quick Ratio3.23
Book Value/Sh2.29 USD
Cash/Share1.49 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.75 USD
Upside (mean)+156.5%
Target Range16.00 USD – 50.00 USD
16.00+156.5% to mean50.00
# Analysts8
Ownership
Shares Out.96.04M
Float53.75M
Insiders16.39%
Institutions70.50%
Short Interest
Short Ratio5.4d
Short % Float5.83%
Short % Out.4.18%
Shares Short4.01M
Short (prev mo.)3.74M
Technical
SMA 5012.86 (-15.8%)
SMA 20010.11 (+7.0%)
Beta1.35
S&P 52W Chg16.45%
Avg Vol (30d)965.79K
Avg Vol (10d)1.21M
Technical Indicators
RSI (14)35.2
MACD-0.6526
MACD Signal-0.5328
MACD Hist.-0.1199
BB Upper14.01 USD
BB Middle11.87 USD
BB Lower9.740 USD
BB Width35.95%
ATR (14)0.6136 USD
Vol Ratio (20d)2.37x